Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
As a leader in the field of CAR-T therapy development, Creative Biolabs offers a comprehensive series of GYPA molecular-related products to support researchers in their quest to develop innovative and effective treatments. To find the appropriate product for you, please look through the list below.
C3AR1 (complement component 3a receptor 1) is a protein that is involved in the immune system response. It is a receptor that binds to the complement component C3a, which is a part of the innate immune system. The activation of C3AR1 by binding to C3a can lead to a series of cellular responses, including the release of pro-inflammatory mediators, chemotaxis of immune cells, and modulation of adaptive immune responses. It has been found that C3AR1 expression is dysregulated in certain types of cancer, including breast, lung, and colorectal cancer. C3AR1 has been implicated in both tumor promotion and inhibition, depending on the context and specific tumor type. For example, studies have shown that C3AR1 expression is upregulated in breast cancer cells and is related to enhanced migration and invasion abilities. Targeting C3AR1 in cancer therapy has shown promise in preclinical studies and is an area of ongoing research.
Fig.1 Structure of C3aR:C3a.1
Breast cancer
Lung cancer
Colorectal cancer
CAR-T in vitro assays enable researchers to evaluate the efficacy and safety of CAR-T cells before implementing them in clinical trials. At Creative Biolabs, we provide various in vitro assays used to assess the function and behavior of anti-C3AR1 CAR-T cells. By utilizing these in vitro assays, researchers can gain valuable insights into the behavior and function of anti-C3AR1 CAR-T cells, guiding the development of more effective CAR-T-based cancer therapies. Our services include the following assays:
In order to further validate the results obtained from the in vitro experiments, we have also developed in vivo models and assays to analyze the impact of anti-C3AR1 CAR-T cells on tumor growth and progression. The most widely used CAR-T in vivo model is the mouse xenograft model. The in vivo models allow us to assess the efficacy and safety of CAR-T therapy in a living organism.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-0120ZP2283 | Anti-C3AR1 (3G7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3G7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2313 | Anti-C3AR1 (7/4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7/4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| XS-0622-ZP3288 | Anti-C3AR1 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3460 | Anti-C3AR1 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0822-YF955 | Anti-Human C3AR1 (XW-35) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-35 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF956 | Anti-Human C3AR1 (XW-36) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-36 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF957 | Anti-Human C3AR1 (XW-37) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-37 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF958 | Anti-Mouse C3AR1 (XW-38) m(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-38 | Rat | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1875 | Anti-Human C3AR1 (XW-35) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-35 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1876 | Anti-Human C3AR1 (XW-36) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-36 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1877 | Anti-Human C3AR1 (XW-37) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-37 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1878 | Anti-Mouse C3AR1 (XW-38) m(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-38 | Rat | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0123-ZP405 | Anti-C3AR1 (2A1) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 2A1 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP406 | Anti-C3AR1 (3G7) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 3G7 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP407 | Anti-C3AR1 (25H10) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 25H10 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP611 | Anti-C3AR1 (CB-P101) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | CB-P101 | Rat | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP405 | Anti-C3AR1 (2A1 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 2A1 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP406 | Anti-C3AR1 (3G7 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 3G7 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP407 | Anti-C3AR1 (25H10 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 25H10 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP611 | Anti-C3AR1 (CB-P101 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | CB-P101 | Rat | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
